Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (TYO 6523), today announced a strategic partnership with venture-backed health technology startup Sava Technologies to support the introduction and future commercialization of its innovative wearable microsensor. The partnership comprises an exclusive commercialization and distribution agreement, initially in Europe, and a concurrent financing agreement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008725757/en/

Ascensia Diabetes Care has announced a strategic partnership with health technology startup Sava Technologies to support the introduction and commercialization of its innovative wearable microsensor.

Under this agreement, Ascensia has been appointed the exclusive distribution partner for Sava’s microsensor technology currently under development. The technology is being designed to continuously monitor relevant biomarkers and molecules, starting with glucose, just beneath the skin. Compared to traditional continuous glucose monitors (CGMs) on the market, Sava’s microsensor technology will offer a minimally invasive approach to glucose monitoring while providing additional insights to users.

Sava is planning for a pivotal clinical study for its CGM technology this year and aims to obtain CE approval and launch the microsensor within the next 18 to 24 months for non-adjunctive use. This would allow insulin dosing decisions without routine blood glucose monitoring confirmation. The companies plan for the CGM to be available through retail channels and under established reimbursement structures, which aligns with the go-to-market approach of Ascensia’s core business in blood glucose monitoring. Subject to regulatory approval, Ascensia plans to begin distribution in Europe, where both companies are headquartered.

Ascensia led the Series B financing round and has made a strategic equity investment in Sava. The long-term potential of Sava’s microsensor technology goes beyond glucose and can open the door to new ways of monitoring health and disease. This approach to using precision technology to create more personalized approaches to healthcare supports the vision of Ascensia’s parent company, PHC Holdings Corporation, which is known collectively with its subsidiaries as PHC Group.

Peter Bodlund, Chief Executive Officer of Ascensia, commented: “Microsensors have the potential to transform the day-to-day monitoring experience for people with diabetes. By bringing together Sava’s innovative technology with Ascensia’s deep diabetes expertise, strong reputation and commercial capabilities, we have an exciting opportunity to address important unmet needs in diabetes care. This is an exciting step for Ascensia as we continue to broaden our portfolio and pursue our ambition to simplify and improve life for people with diabetes.”

Rafaël Michali, Co-Founder and Co-CEO of Sava, commented: “Ascensia has spent decades earning the trust of people with diabetes and the clinicians who support them. Their strong global commercial organization, combined with our novel microsensor platform, gives us a route to a different monitoring experience at the scale this challenge demands. This partnership is the first step towards bringing that technology to the millions of people who need it.”

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR^® portfolio of blood glucose monitoring systems. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 90 countries, with direct commercial organizations in 29 countries worldwide. For further information, please visit the Ascensia Diabetes Care website at http://www.ascensia.com.

About Sava

Sava is a venture-backed consumer and medical device company developing a wearable biosensor platform that detects molecules just beneath the skin. Headquartered in London, Sava's novel microsensor technology monitors biomarkers painlessly and in real time - starting with, but not limited to, glucose. www.sava.health

Join Sava's waiting list at www.sava.health/waiting-list.

About PHC Holdings Corporation

PHC Holdings Corporation (TYO 6523) is a global collection of healthcare companies with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2025 were JPY 364.4 billion with global distribution of products and services in more than 125 countries. www.phchd.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20261008725757/en/

Media Contacts:
Ascensia Diabetes Care
Lorraine Chandler
lorraine.chandler@ascensia.com

PHC Holdings Corporation
Julia Cottrill
julia.cottrill@phchd.com

Sava Technologies
Gea Donadoni
gea@sava.health

Logo

Images

Tags

More Like This

Ascensia Diabetes Care Appoints Peter Bodlund as President and Chief Executive Officer

SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026

This Is the Moment Everything Changed: Ascensia Launches Global Art and Photography Competition for World Diabetes Day

Xsensio SA Raises $7M Oversubscribed Series A, Accelerates Clinical Deployment of Continuous Biosensing

Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices

SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring

A. Menarini Diagnostics and Sinocare Announce Exclusive Distribution Agreement for New Continuous Glucose Monitoring System

SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)